Active Not RecruitingNCT05407636
Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD
PHASE3 · 735 planned enrolment
- Countries listed
- 10
- Registry update
- August 3, 2026
Registry Intervention View
ABBV-RGX-314 Dose 1
Trial registrations containing the exact intervention label ABBV-RGX-314 Dose 1.
Exact registry label · Not reported
2 linked registrations
No aliases or equivalent products have been inferred.
Topics connected by trial metadata
0 linked registrations report posted results
This is a registry availability fact, not a safety result, comparison, or conclusion.
Understand the safety boundary →Registered trials
Active Not RecruitingNCT04514653
RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Neovascular Age-Related Macular Degeneration (nAMD)
PHASE2 · 146 planned enrolment
- Countries listed
- 1
- Registry update
- February 27, 2026